Genous promotes tissue healing of stent-related injuries in a rapid and controlled manner, unlike drug eluting stents, which indiscriminately inhibit healing reactions using anti-proliferative drugs. Genous captures circulating endothelial progenitor cells (EPCs) to accelerate natural healing. This innovative approach protects against thrombosis and minimizes restenosis. Welcome to the new era of Bio-engineered stents.
Bone marrow derived EPCs circulate in the blood stream. |
Genous with anti-hCD34 antibody on the stent surface captures EPCs. |
EPCs mature into endothelial cells, healing the artery with restored endothelium. |
A unique surface priming process prepares a functionalized surface on the bare metal stent. The following bio-chemical reaction results in a biocompatible intermediate matrix. Covalent bonding then achieves antibody attachment. EPCs originate from bone marrow and circulate through the bloodstream. EPCs are captured by antibodies and immobilized on the stent surface. EPC capture, division, and migration continue until a confluent functional endothelial layer is formed between the stent struts.
To give the Genous concept an appropriate stent platform, we employ our uniquely designed coronary R stent. Its patented dual helix configuration provides omni-directional flexibility and extremely high radial strength. The stent's cells can be expanded to up to 4.5 mm in diameter, to enable excellent side branch access for bifurcation stenting.
Stent | ||
Strut dimensions: | 0.0035" (0.09 mm) x 0.0040" (0.10 mm) | |
Radiopacity: | Moderate | |
Material: | 316L stainless steel | |
Side branch access: | 4.5 mm | |
Foreshortening: | < 1 %* | |
Recoil: | < 4 %* | |
Vessel wall coverage: | 17 %* | |
Radial force (to collapse): | > 25 psi* | |
Balloon Catheter |
||
Proximal shaft: | Hypotube | |
Nominal pressure: | 9 atm | |
Rated burst pressure: | 16 atm | |
Avg. burst pressure: | 27 atm* | |
Nominal crossing profile: | 0.043" (1.09 mm)* | |
Catheter tip length: | 5.0 mm | |
Max. guidewire OD: | 0.014" | |
Shaft (prox/distal): | 2.2F/2.9F | |
Guiding catheter compatibility: | 5F (0.057" ID min) for 2.5, 2.75 mm and 6F (0.068" ID min) for 3.0, 3.5, and 4.0 mm |
|
Ordering Information
(mm) | LENGTH (mm) | |||||||
9 | 13 | 15 | 18 | 23 | 28 | 33 | ||
2.5 | 225-092-5 | 225-132-5 | 225-152-5 | 225-182-5 | 225-232-5 | |||
2.75 | 227-092-5 | 227-132-5 | 227-152-5 | 227-182-5 | 227-232-5 | |||
3.0 | 230-092-5 | 230-132-5 | 230-152-5 | 230-182-5 | 230-232-5 | 230-282-5 | 230-332-5 | |
3.5 | 235-092-5 | 235-132-5 | 235-152-5 | 235-182-5 | 235-232-5 | 235-282-5 | 235-332-5 | |
4.0 | 240-092-5 | 240-132-5 | 240-152-5 | 240-182-5 | 240-232-5 | 240-282-5 | 240-332-5 | |
Bone marrow derived EPCs
|
Genous with anti-hCD34
|
EPCs mature into endothelial cells, healing the artery with restored endothelium. |
Stent | ||
Strut dimensions: | 0.0034" (0.09 mm, width) x 0.0032" (0.08 mm, thickness) | |
Radiopacity: | Moderate | |
Material: | L605 cobalt chromium alloy | |
Side branch access: | 4.5 mm | |
Foreshortening: | < 2 %* | |
Recoil: | < 5 %* | |
Vessel wall coverage: | 14 %* | |
Radial force (to 50% lumen collapse): | 26 Psi* | |
Balloon Catheter |
||
Proximal shaft: | Hypotube | |
Nominal pressure: | 9 atm | |
Rated burst pressure: | 16 atm | |
Avg. burst pressure: | > 28 atm | |
Nominal crossing profile: | 0.038" (0.97 mm)* | |
Catheter tip length: | 4.25 mm | |
Max. guidewire OD: | 0.014" | |
Shaft (prox/distal): | 2.3F/2.9F | |
Guiding catheter compatibility: | 5F (0.056" ID min) | |
Ordering Information
(mm) | LENGTH (mm) | |||||||
9 | 13 | 15 | 18 | 23 | 28 | 33 | ||
2.5 | 225-092-7 | 225-132-7 | 225-152-7 | 225-182-7 | 225-232-7 | |||
2.75 | 227-092-7 | 227-132-7 | 227-152-7 | 227-182-7 | 227-232-7 | |||
3.0 | 230-092-7 | 230-132-7 | 230-152-7 | 230-182-7 | 230-232-7 | 230-282-7 | 230-332-7 | |
3.5 | 235-092-7 | 235-132-7 | 235-152-7 | 235-182-7 | 235-232-7 | 235-282-7 | 235-332-7 | |
4.0 | 240-092-7 | 240-132-7 | 240-152-7 | 240-182-7 | 240-232-7 | 240-282-7 | 240-332-7 | |
The Genous Bio-engineered surface features antibodies immobilized on the stent that capture circulating endothelial progenitor cells (EPCs), which in turn rapidly form an endothelial layer over and between the stent struts. This protects against thrombus and minimizes restenosis.
Nebras aims to be the market leader in the field of Biomedical Equipment and Medical Supplies to supply healthcare organizations with latest innovations, best quality and value added products to Jordan and Middle East's communities and to share in developing the healthcare industry in the Middle East. Nebras works constantly to improve customer satisfaction, and employee opportunity and shareholder value.
For supplying of pharmaceuticals from different manufacturers in Jordan
For supplying pharmaco- herbal products